Clinical trials: Allogenic Disease
Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
This phase II trial studies how well vorinostat and combination chemotherapy before donor stem cell transplantation work in treating patients with aggressive B-cell or T-cell non-Hodgkin lymphoma that has come back (relapsed).
- Conditions
- Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04220008
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Clofarabine
- Sponsor
- M.D. Anderson Cancer Center
Duchenne Muscular Dystrophy, Cardiomyopathy
HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)
Male participants with cardiomyopathy secondary to Duchenne muscular dystrophy (DMD) meeting all inclusion and no exclusion criteria will be randomized. All participants will be at least 12 years of age.
- Trial name
- HOPE (NCT02485938)
- Testing
- Allogeneic Cardiosphere-Derived Cells (CAP-1002)
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Capricor Inc.
Paraquat Poisoning, Lung Injury
Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Paraquat Poisoning Induced Lung Injury
Phase I-II Clinical Trial-Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with paraquat poisoning induced lung injury, randomized,single blind, controlled prospective study.
- Trial name
- UCMSC-PQLI (NCT02444858)
- Testing
- UCMSC group, Control group(Normal saline)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Polymyositis, Dermatomyositis
Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis
The efficacy of PN-101 in subjects with polymyositis or dermatomyositis will be evaluated at Week 12 using IMACS-TIS in comparison with the placebo control group.
- Trial name
- NCT07122648
- Testing
- PN-101
- Where
- 5 sites in South Korea
- Volunteers
- 36 people
- Sponsor
- Paean Biotechnology Inc.
COVID-19
Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19
Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as treatment for patients suspected to have COVID-19.
- Trial name
- NCT04362189
- Testing
- HB-adMSC
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Hope Biosciences Research Foundation
Peripheral T-cell Lymphomas, Lymphoproliferative Disorders
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause.
- Conditions
- Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
- Trial name
- NCT03922724
- Testing
- ATL-RIC, mRIC, allo HCT
- Where
- 2 sites in United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Cystic Fibrosis
Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis
A Safety Run-In will be followed by a Double-Blinded Randomized Phase. All subjects shall meet the inclusion/exclusion criteria, and will be evaluated prior to the scheduled infusion to establish baseline.
- Trial name
- HAPI (NCT03058068)
- Testing
- Allo-hMSCs
- Sponsor
- Joshua M Hare
Ketoacidosis, Diabetic
Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation for Type 1 Diabetes With Diabetic Ketoacidosis
This is a phase II trial in individuals who have been diagnosed with type 1 diabetes within the previous 12 months and suffered from diabetic ketoacidosis at onset of disease.
- Trial name
- UCMSCDKA (NCT02763423)
- Testing
- umbilical cord mesenchymal stem cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia
CD19-Specific T Cells Post AlloSCT
This phase I trial investigates the side effects and best dose of CD19 positive (+) specific CAR-T cells in treating patients with CD19+ lymphoid malignancies, such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, small…
- Conditions
- B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT03579888
- Testing
- Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Non Hodgkin Lymphoma, Hodgkin Lymphoma
Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving disease eradication in patients with…
- Trial name
- NCT01079013
- Testing
- treosulfan
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Sheba Medical Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
This phase I trial studies how well the combination of magrolimab works with azacitidine after a donor stem cell transplant (allogeneic hematopoietic cell transplantation) in treating patients with high-risk acute myeloid…
- Trial name
- NCT05823480
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection
- Sponsor
- City of Hope Medical Center
Brain Metastases, Leptomeningeal Metastasis
Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy
This is a prospective, single-center, phase 1 basket trial that will evaluate the safety and feasibility of administering SV-BR-1-GM in combination with pembrolizumab to solid tumor oncology patients over nine cycles.
- Trial name
- NCT07199413
- Testing
- SV-BR-1-GM Vaccine, Cyclophosphamide, Pembrolizumab
- Sponsor
- Medical College of Wisconsin
Acute Myeloid Leukemia
TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete Remission
Acute myeloid leukemia (AML) is a serious blood cancer that mainly affects older adults. For patients who achieve their first complete remission (CR1), allogeneic hematopoietic stem cell transplantation (HSCT) may provide a…
- Trial name
- TBF-AML (NCT07563920)
- Testing
- Thiotepa, Busulfan (BU), Fludarabine
- Volunteers
- 93 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hidradenitis Suppurativa
Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa
Multicenter Phase I/II Clinical Trial to Evaluate Safety and Efficiency of Allogenic Adult Mesenchymal Stem Cell from Adipose Tissue in Patients With Hidradenitis Suppurativa
- Trial name
- NCT05934825
- Testing
- Injectable suspension of allogeneic adult mesenchymal stem cells
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Andalusian Network for Design and Translation of Advanced Therapies
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
Graft-versus-host disease (GVHD) contributes substantially to transplant-related morbidity and mortality. Steroids remains first line therapy for acute GVHD but there is currently no consensus on second line therapy for those in…
- Trial name
- NCT00563108
- Testing
- Basiliximab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hospital Authority, Hong Kong
Aml, AML, Adult
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
This is a phase I clinical trial that will define the maximum tolerated dose (MTD) and investigate the feasibility and safety of the combination of nivolumab and azacitidine after reduced-intensity allogeneic PBSC…
- Trial name
- NCT04128020
- Testing
- Nivolumab, Azacitidine
- Sponsor
- Sherif Farag
Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
This phase Ib trial studies the side effects of combination chemotherapy and donor stem cell transplant followed by ixazomib citrate maintenance therapy in treating patients with multiple myeloma that has returned after a period…
- Trial name
- NCT02504359
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- OHSU Knight Cancer Institute
Leukemia, Lymphoma
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. White blood cells from donors may be able to prevent graft-versus-host disease in patients with hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005946
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Acute Myeloid Leukemia and Myelodysplastic Syndrome
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
The purpose of the study is to determine the safety and benefit of nivolumab, ipilimumab or the combination of nivolumab with ipilimumab given after bone marrow transplant for patients with acute myelogenous leukemia and…
- Trial name
- CPIT-002 (NCT02846376)
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Hackensack Meridian Health
Acute Myeloid Leukemia, Allogeneic Transplantation
Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation
Study Design: prospective phase II trial with 30 patients in 1 site Treatment Scheme: Option 1: Patient < 60 years of age with relapse after chemotherapy or > 12 months after hematopoetic stem cell transplantation Mylotarg 6 mg/…
- Trial name
- NCT00460447
- Testing
- Gemtuzumab Ozogamicin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Carl Gustav Carus